Metagenomi Inc
NASDAQ:MGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Metagenomi Inc
NASDAQ:MGX
|
US |
|
Companhia Energetica do Rio Grande do Norte Cosern
BOVESPA:CSRN3
|
BR |
|
Webis Holding PLC
LSE:WEB
|
IM |
|
C
|
Curzio Research Inc
OTC:CURZ
|
US |
|
RTG Mining Inc
TSX:RTG
|
AU |
|
Adobe Inc
NASDAQ:ADBE
|
US |
|
T
|
True North Commercial REIT
TSX:TNT.UN
|
CA |
|
V
|
Viji Finance Ltd
NSE:VIJIFIN
|
IN |
|
BOE Technology Group Co Ltd
SZSE:000725
|
CN |
Metagenomi Inc
Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
